These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 34154502)

  • 21. Detection of CD55- and/or CD59-deficient red cell populations in patients with lymphoproliferative syndromes.
    Meletis J; Terpos E; Samarkos M; Meletis C; Apostolidou E; Komninaka V; Korovesis K; Mavrogianni D; Boutsis D; Variami E; Viniou N; Konstantopoulos K; Loukopoulos D
    Hematol J; 2001; 2(1):33-7. PubMed ID: 11920231
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Flow cytometric analysis of glycosylphosphatidyl-inositol-anchored proteins to assess paroxysmal nocturnal hemoglobinuria clone size.
    Piedras J; López-Karpovitch X
    Cytometry; 2000 Aug; 42(4):234-8. PubMed ID: 10934342
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytokines affect resistance of human renal tumour cells to complement-mediated injury.
    Blok VT; Gelderman KA; Tijsma OH; Daha MR; Gorter A
    Scand J Immunol; 2003 Jun; 57(6):591-9. PubMed ID: 12791098
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Extracellular Vesicles Isolated from Plasma of Multiple Myeloma Patients Treated with Daratumumab Express CD38, PD-L1, and the Complement Inhibitory Proteins CD55 and CD59.
    Brennan K; Iversen KF; Blanco-Fernández A; Lund T; Plesner T; Mc Gee MM
    Cells; 2022 Oct; 11(21):. PubMed ID: 36359760
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of membrane complement regulators, CD46, CD55 and CD59, in mesothelial cells of patients on peritoneal dialysis therapy.
    Sei Y; Mizuno M; Suzuki Y; Imai M; Higashide K; Harris CL; Sakata F; Iguchi D; Fujiwara M; Kodera Y; Maruyama S; Matsuo S; Ito Y
    Mol Immunol; 2015 Jun; 65(2):302-9. PubMed ID: 25725314
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression levels of complement regulatory proteins (CD35, CD55 and CD59) on peripheral blood cells of patients with chronic kidney disease.
    Eldewi DM; Alhabibi AM; El Sayed HME; Mahmoud SAK; El Sadek SM; Gouda RM; Hassan MAEM; Ibrahim AH; Abd El Haliem NF
    Int J Gen Med; 2019; 12():343-351. PubMed ID: 31571973
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of complement regulatory proteins CR1, DAF, MCP and CD59 in haematological malignancies.
    Guc D; Canpinar H; Kucukaksu C; Kansu E
    Eur J Haematol; 2000 Jan; 64(1):3-9. PubMed ID: 10680700
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Membrane-bound regulators of complement activation in uveal melanomas. CD46, CD55, and CD59 in uveal melanomas.
    Goslings WR; Blom DJ; de Waard-Siebinga I; van Beelen E; Claas FH; Jager MJ; Gorter A
    Invest Ophthalmol Vis Sci; 1996 Aug; 37(9):1884-91. PubMed ID: 8759358
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early and extensive CD55 loss from red blood cells supports a causal role in malarial anaemia.
    Gwamaka M; Fried M; Domingo G; Duffy PE
    Malar J; 2011 Dec; 10():386. PubMed ID: 22206234
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Complement control proteins, CD46, CD55, and CD59, as common surface constituents of human and simian immunodeficiency viruses and possible targets for vaccine protection.
    Montefiori DC; Cornell RJ; Zhou JY; Zhou JT; Hirsch VM; Johnson PR
    Virology; 1994 Nov; 205(1):82-92. PubMed ID: 7526538
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The complement receptors CD46, CD55 and CD59 are regulated by the tumour microenvironment of head and neck cancer to facilitate escape of complement attack.
    Kesselring R; Thiel A; Pries R; Fichtner-Feigl S; Brunner S; Seidel P; Bruchhage KL; Wollenberg B
    Eur J Cancer; 2014 Aug; 50(12):2152-61. PubMed ID: 24915776
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Complement activation in the plasma and placentas of women with different subsets of antiphospholipid syndrome.
    Scambi C; Ugolini S; Tonello M; Bortolami O; De Franceschi L; Castagna A; Lotti V; Corbella M; Raffaelli R; Caramaschi P; Mattia E; Biasi D; Ruffatti A
    Am J Reprod Immunol; 2019 Dec; 82(6):e13185. PubMed ID: 31479579
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis.
    Golay J; Zaffaroni L; Vaccari T; Lazzari M; Borleri GM; Bernasconi S; Tedesco F; Rambaldi A; Introna M
    Blood; 2000 Jun; 95(12):3900-8. PubMed ID: 10845926
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-level co-expression of complement regulators on vascular endothelium in transgenic mice: CD55 and CD59 provide greater protection from human complement-mediated injury than CD59 alone.
    Cowan PJ; Shinkel TA; Aminian A; Romanella M; Wigley PL; Lonie AJ; Nottle MB; Pearse MJ; d'Apice AJ
    Xenotransplantation; 1998 Aug; 5(3):184-90. PubMed ID: 9741456
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Silencing EGFR-upregulated expression of CD55 and CD59 activates the complement system and sensitizes lung cancer to checkpoint blockade.
    Shao F; Gao Y; Wang W; He H; Xiao L; Geng X; Xia Y; Guo D; Fang J; He J; Lu Z
    Nat Cancer; 2022 Oct; 3(10):1192-1210. PubMed ID: 36271172
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Critical protection from renal ischemia reperfusion injury by CD55 and CD59.
    Yamada K; Miwa T; Liu J; Nangaku M; Song WC
    J Immunol; 2004 Mar; 172(6):3869-75. PubMed ID: 15004194
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alteration of membrane complement regulators is associated with transporter status in patients on peritoneal dialysis.
    Kitterer D; Biegger D; Segerer S; Braun N; Alscher MD; Latus J
    PLoS One; 2017; 12(5):e0177487. PubMed ID: 28542228
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Membrane-bound complement regulatory proteins are prognostic factors of operable breast cancer treated with adjuvant trastuzumab: a retrospective study.
    Liu M; Yang YJ; Zheng H; Zhong XR; Wang Y; Wang Z; Wang YG; Wang YP
    Oncol Rep; 2014 Dec; 32(6):2619-27. PubMed ID: 25241923
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The use of monoclonal antibodies and flow cytometry in the diagnosis of paroxysmal nocturnal hemoglobinuria.
    Hall SE; Rosse WF
    Blood; 1996 Jun; 87(12):5332-40. PubMed ID: 8652849
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Expression of CD55 and CD59 in chronic rhinosinusitis and its significance].
    Xia L; Wang Y; Gao W; Gao H
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2014 Dec; 49(12):1021-3. PubMed ID: 25623871
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.